```html

Gouty Tenosynovitis – Comprehensive Medical Guide

Overview

Gouty tenosynovitis is an inflammatory condition in which urate crystals deposit in the tendon sheath (the protective covering that surrounds a tendon). The presence of these monosodium urate (MSU) crystals triggers an intense inflammatory response, causing pain, swelling, and restricted movement of the affected joint. While most people associate gout with the big toe, gouty tenosynovitis can involve any tendon sheath—most commonly the wrist, hand, ankle, or foot.

Who it affects: The condition most often occurs in adults ≥ 40 years old, and its prevalence mirrors that of hyperuricemia and gout, which affect about 4% of the U.S. adult population (≈ 13 million people) and up to 7% globally. Men are three‑to‑four times more likely to develop gouty tenosynovitis than women, largely because they tend to have higher serum uric acid levels. Post‑menopausal women and individuals with chronic kidney disease, obesity, or a family history of gout are also at increased risk.

Symptoms

Symptoms develop suddenly or over a few days and may fluctuate with uric‑acid levels. Common manifestations include:

• Localized pain: Sharp, throbbing or aching pain directly over the tendon sheath; pain often worsens with movement or pressure.
• Swelling (tenosynovial effusion): Visible puffiness that may feel warm to the touch.
• Redness and heat: The skin over the affected area may appear erythematous and feel hotter than surrounding tissue.
• Stiffness: Decreased range of motion; simple tasks such as gripping a pen or walking may become painful.
• Crepitus: A crackling sensation felt when moving the tendon, caused by inflammation within the sheath.
• Systemic signs (occasionally): Low‑grade fever, malaise, or a feeling of general “flu‑like” illness, especially during an acute gout flare.
• Recurrence: After the initial episode resolves, future flares may occur in the same or different tendon sheaths, often precipitated by dietary triggers or medication changes.

Causes and Risk Factors

Underlying cause

Gouty tenosynovitis is a manifestation of gout. When serum uric acid (sUA) exceeds its solubility threshold (≈ 6.8 mg/dL), monosodium urate crystals can form and deposit in joints and soft tissues, including tendon sheaths. The immune system recognizes these crystals as foreign, releasing cytokines (IL‑1β, TNF‑α) that drive the acute inflammatory cascade.

Major risk factors

• Hyperuricemia: Persistent sUA > 6.8 mg/dL (≈ 404 µmol/L).
• Dietary factors: High intake of purine‑rich foods (red meat, organ meats, seafood), fructose‑sweetened beverages, and excessive alcohol (especially beer).
• Obesity: Body mass index (BMI) ≥ 30 kg/m² is associated with a 2–3‑fold increased gout risk.
• Renal impairment: Reduced uric‑acid excretion (eGFR < 60 mL/min/1.73 m²).
• Medications: Loop diuretics, thiazides, low‑dose aspirin, and some immunosuppressants raise sUA.
• Genetics: Variants in SLC2A9, ABCG2, and other urate‑transport genes.
• Medical comorbidities: Hypertension, metabolic syndrome, diabetes, and cardiovascular disease.
• Sex and age: Male sex; incidence rises after age 40, peaking in the 60s.
• Previous gout attacks: History of gouty arthritis predicts future soft‑tissue involvement.

Diagnosis

Accurate diagnosis relies on a combination of clinical assessment, imaging, and laboratory analysis.

Clinical evaluation

• Detailed history of gout or hyperuricemia, dietary habits, medication use, and family history.
• Physical examination focusing on tenderness, swelling, and temperature of the tendon sheath.

Laboratory tests

• Serum uric acid: Elevated levels support the diagnosis but are not definitive; up to 30% of acute gout flares occur with normal sUA.
• Synovial fluid analysis: Aspiration of fluid from the tendon sheath and microscopy under polarized light reveals negatively birefringent, needle‑shaped MSU crystals – the gold‑standard diagnostic test.
• Complete blood count (CBC) and inflammatory markers (CRP, ESR) may be elevated during an acute flare.

Imaging studies

• Ultrasound: Sensitive for detecting tophaceous deposits (double‑contour sign) and fluid in the sheath.
• Dual‑energy CT (DECT): Can differentiate MSU crystals from calcium deposits, useful when fluid aspiration is difficult.
• MRI: Shows tendon sheath thickening, edema, and associated joint involvement, helpful for ruling out infection or other rheumatologic conditions.

Treatment Options

Therapeutic goals are to relieve pain, resolve inflammation, and prevent future attacks.

Acute management

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): Indomethacin 50 mg PO q6 h, naproxen 500 mg PO bid, or ibuprofen 400 mg PO q6 h, unless contraindicated (e.g., renal disease, ulcer disease).
• Colchicine: 1.2 mg PO loading dose followed by 0.6 mg 1 h later, then 0.6 mg once or twice daily for 2–3 days. Dose adjustment is required for renal insufficiency.
• Corticosteroids: Prednisone 30–40 mg PO daily for 5–7 days, or intra‑sheath triamcinolone injection (10–40 mg) for patients who cannot take NSAIDs/colchicine.

Urate‑lowering therapy (ULT) – long‑term

Initiated after the acute episode resolves, especially in patients with:

• Recurrent gout attacks (≥ 2 per year).
• Urate‑deposition disease (tophi, gouty tenosynovitis, urate kidney stones).
• Chronic kidney disease stage 3‑4.

Common ULT agents:

• Allopurinol: Start 100 mg PO daily; increase by 100 mg every 2–4 weeks until sUA < 6 mg/dL. Test for HLA‑B*58:01 in Asian patients to avoid severe hypersensitivity.
• Febuxostat: 40 mg PO daily, titrated to 80 mg if needed; preferred in mild‑to‑moderate renal disease.
• Probenecid: 250 mg PO bid; enhances renal uric‑acid excretion; use only when GFR > 50 mL/min.
• Uricase agents (pegloticase, rasburicase): Intravenous enzyme therapy for refractory gout; administered in specialist centers.

Lifestyle and adjunct measures

• Hydration: Aim for > 2 L water daily to promote uric‑acid excretion.
• Dietary modification: Limit purine‑rich foods, reduce fructose intake, avoid alcohol (especially beer).
• Weight loss: 5–10% reduction in body weight can lower sUA by 0.5–1 mg/dL.
• Physical therapy: Gentle range‑of‑motion exercises after the acute phase improve tendon glide and prevent stiffness.

Living with Gouty Tenosynovitis

Daily management tips

• Keep a symptom diary: note food, alcohol, medication changes, and flare timing.
• Wear supportive footwear and cushioned orthotics if the foot/ankle is involved.
• Apply intermittent cold packs (10‑15 min) during flare to decrease swelling.
• Gentle stretching of the affected tendon after pain subsides (e.g., wrist flexor/extensor stretches) to maintain flexibility.
• Take prescribed ULT consistently; do not stop when asymptomatic.
• Schedule regular lab checks: sUA every 2–4 weeks during titration, then every 3–6 months.
• Coordinate care with a rheumatologist if flares are frequent or if you have comorbidities.

Psychosocial aspects

Recurrent gout attacks can affect work productivity and quality of life. Consider counseling, support groups, or patient education programs offered by organizations such as the Arthritis Foundation.

Prevention

Preventing gouty tenosynovitis is essentially the same as preventing gout itself:

• Maintain serum uric acid < 6 mg/dL (or < 5 mg/dL if tophi are present).
• Adopt a Mediterranean‑style diet rich in vegetables, low‑fat dairy, whole grains, and nuts.
• Limit alcohol (≤ 1 drink/day for women, ≤ 2 drinks/day for men) and avoid binge drinking.
• Stay physically active – at least 150 min of moderate aerobic activity weekly.
• Review medications with your physician; switch from high‑risk diuretics to alternatives when possible.
• Control comorbid conditions: blood pressure, blood glucose, and lipid levels.

Complications

If left untreated or poorly managed, gouty tenosynovitis can lead to:

• Chronic tendon damage: Fibrosis and rupture due to repeated inflammation.
• Tophi formation within the sheath: Large crystal deposits that may erode bone or skin.
• Joint degeneration: Secondary osteoarthritis from persistent inflammation.
• Infection: Inflamed tendon sheaths are more susceptible to bacterial superinfection, especially after corticosteroid injection.
• Kidney stones: Urate stones develop in up to 20% of chronic gout patients.
• Cardiovascular risk: Hyperuricemia is an independent risk factor for hypertension and coronary disease.

When to Seek Emergency Care

References

1. Mayo Clinic. Gout – symptoms and causes. https://www.mayoclinic.org
2. Centers for Disease Control and Prevention. Prevalence of Gout in the United States, 2022. https://www.cdc.gov
3. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Gout. https://www.niams.nih.gov
4. Cleveland Clinic. Tenosynovitis: What You Need to Know. https://my.clevelandclinic.org
5. American College of Rheumatology. 2023 Guideline for the Management of Gout. https://www.rheumatology.org
6. World Health Organization. WHO guidelines on lifestyle and gout risk, 2022.
7. Dalbeth N, et al. “Gout and its treatment: Advances and challenges.” *Lancet* 2021;397:539‑552.

```